Recently, a phase Ib/II trial (NCT01359657) of another anti-CXCR4 antibody, ulocuplumab (BMS-936564), confirmed that blockade of the CXCR4–CXCL12 axis by this mAb is safe, with acceptable adverse effects, and leads to a high response rate in combination with lenalidomide and dexamethasone in patients with relapsed/refractory myeloma [148]. The gene discussed is CXCR4; the disease is plasma cell myeloma.